Pyrilutamide (KX-826) is a topical nonsteroidal antiandrogen (NSAA) developed by Suzhou Kintor Pharmaceuticals for treating androgenetic alopecia (AGA). It acts as a selective high-affinity silent antagonist of the androgen receptor (AR), blocking testosterone and DHT from binding to hair follicle ARs, thereby preventing hair follicle miniaturization.
Ongoing Studies:
– A long-term safety phase III trial in China is enrolling 271 male and female patients for a 52-week treatment period.
– A phase Ib/III clinical trial combining KX-826 with minoxidil for male AGA in China has been approved.
The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.
Sources:
https://en.wikipedia.org/wiki/Pyrilutamide
https://www.medkoo.com/products/49841
https://folliclethought.com/kintor-pharmaceutical-kx-826-phase-2-results-with-poster/
